KLK4

Aliases:
This biomarker is also known as:
  • Serine protease 17
  • Enamel matrix serine proteinase 1
  • EMSP1
  • PRSS17
  • Prostase
  • Kallikrein-4
  • hK4
  • KLK4
  • KLK-L1
  • Human kallikrein 4
  • PSTS
  • Kallikrein-like protein 1

Description…

The glandular kallikreins are a distinct group of serine proteases with molecular masses of 25,000 to 40,000. Kallikreins are a subgroup of serine proteases having diverse physiological functions. Growing evidence suggests that many kallikreins are implicated in carcinogenesis and some have potential as novel cancer and other disease biomarkers. This gene is one of the fifteen kallikrein subfamily members located in a cluster on chromosome 19. Several human kallikrein genes have been isolated. hK4 is expressed in the prostate.

Datasets

There are no datasets associated with this biomarker.

Attributes
QA State: Accepted
Type: Protein
HGNC Name: KLK4

The following organs have data associated with this biomarker…

Attributes

Phase: 2
QA State: Accepted

Overview

Kallikreins (KLKs) are highly conserved serine proteases that play key roles in a variety of physiological and pathological processes. KLK4 is regulated by androgens and is highly specific to prostate for expression. hK4 is intracellularly localized. KLK4 is predominantly expressed in the basal cells of the normal prostate gland and overexpressed in prostate cancer. hK4 has a unique structure and function compared with other members of the KLK family and may have a role in the biology and characterization of prostate cancer.

Performance Comment

hK2, hK4 and hK11 do not distinguish cases from controls in these populations.

Supporting Study Data

The following studies/protocols provide evidence supporting KLK4 indications for the Prostate…

Prostate Rapid Pre-Validation Set

Determine which markers move to validation using the prospectie prostate reference set samples.

View more about this study
Biomarker Characteristics Summary

No statistics found.

Decision Rule

No clinically useful decision rule found.

Additional Study-Specific Protocols
Study-Specific Publications

No study-specific publications defined.

Study-Specific Resources

No study-specific resources defined.

Prostate Rapid Reference Set Application: Brian Haab - Van Andel (2006)

To evaluate TSP-1 as a marker to specifically detect prostate cancer

View more about this study
Biomarker Characteristics Summary

No statistics found.

Decision Rule

No extra decision rule information available

Additional Study-Specific Protocols
Study-Specific Publications

No study-specific publications defined.

Study-Specific Resources

No study-specific resources defined.

Prostate Rapid Reference Set Application: Eleftherios Diamandis - Mt Sinai (2006)

A blinded study coordinated by the EDRN GU Collaborative Group found the biomarker is not associated with prostate cancer risk

View more about this study
Biomarker Characteristics Summary

No statistics found.

Decision Rule

No clinically useful decision rule found.

Additional Study-Specific Protocols
Study-Specific Publications

No study-specific publications defined.

Study-Specific Resources

No study-specific resources defined.

Prostate Reference Set Application: proPSA-Dan Chan-JHU (2008)

Primary Objective – To validate the serum %[-2]proPSA marker for the improvement of diagnosis and risk assessment of prostate cancer and reducing unnecessary biopsies.

View more about this study
Biomarker Characteristics Summary

No statistics found.

Decision Rule

No extra decision rule information available

Additional Study-Specific Protocols
Study-Specific Publications

No study-specific publications defined.

Study-Specific Resources

No study-specific resources defined.

Organ-Specific Protocols

No organ-specific protocols defined.

Organ-Specific Publications

No organ-specific publications defined.

Organ-Specific Resources

No organ-specific resources defined.

Version 5.1.0